Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
Skip to main content

Alfie 2

 

FULL TITLE

Low-molecular-weight heparin to increase the chance of live birth in women with recurrent miscarriage and inherited thrombophilia (Anticoagulants for Living FoEtuses in women with recurrent miscarriage and inherited thrombophilia)

WHO CAN PArticipate in THIS STUDY? 

Women with recurrent miscarriage and inherited thrombophilia, planning a pregnancy or less than 7 weeks pregnant.

ABOUT THE Study 

It is well known that some women whose blood tends to clot more than normal have an increased risk of miscarriage. That clotting tendency is called thrombophilia (sometimes also described as “sticky blood”). 

If this tendency has developed over time, perhaps as part of another illness, it is called “acquired thrombophilia” and treatment with anti-coagulant or “blood-thinning” medication has been shown to reduce the risk of miscarriage.

The situation is different for women who have inherited thrombophilia (i.e. passed down from a parent). Although a large number of studies has shown that they also have a higher than normal risk of miscarriage, it is not clear if anticoagulant medication will reduce that risk or not.

This trial aims to try and find out if anticoagulant (“blood thinning”) treatment reduces the risk of miscarriage in pregnant women who have inherited thrombophilia and who have had at least two consecutive or non-consecutive miscarriages.

ETHICAL APPROVAL 

Ref number 15/WM/0261

CONTACT US TO GET INVOLVED 

If you are interested in taking part, you can use our contact formor  call 01865 572258 or email osprea@wrh.ox.ac.uk